PriceTargets.com logo

Amicus Therapeutics - FOLD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $17.29
  • Forecasted Upside: 57.14%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$11.00 As of 12/17/2025 05:00 PM ET
▲ +0.11 (1.01%)

This chart shows the closing price for FOLD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amicus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FOLD

Analyst Price Target is $17.29
▲ +57.14% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Amicus Therapeutics in the last 3 months. The average price target is $17.29, with a high forecast of $22.00 and a low forecast of $11.00. The average price target represents a 57.14% upside from the last price of $11.00.

This chart shows the closing price for FOLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Amicus Therapeutics. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/17/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/17/2025

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/17/2025CitigroupInitiated CoverageBuy$17.00
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/19/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/6/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$18.00 ➝ $19.00
11/5/2025The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$9.00 ➝ $11.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/6/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/18/2025Needham & Company LLCUpgradeHold ➝ Buy$14.00
7/17/2025Morgan StanleyUpgradeEqual Weight ➝ Overweight
5/2/2025UBS GroupBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
5/2/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$12.00 ➝ $9.00
2/20/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$18.00 ➝ $17.00
2/20/2025Needham & Company LLCReiterated RatingHold ➝ Hold
1/15/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$21.00 ➝ $21.00
1/13/2025Needham & Company LLCReiterated RatingHold ➝ Hold
12/13/2024Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$17.00 ➝ $12.00
11/12/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$16.00 ➝ $17.00
11/7/2024GuggenheimBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
11/7/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$20.00 ➝ $21.00
11/7/2024Needham & Company LLCReiterated RatingHold
10/17/2024Bank of AmericaBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
10/11/2024Morgan StanleyLower TargetOverweight ➝ Overweight$19.00 ➝ $18.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00 ➝ $20.00
9/6/2024Jefferies Financial GroupInitiated CoverageBuy$18.00
8/16/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$17.00 ➝ $16.00
8/9/2024Needham & Company LLCReiterated RatingHold
5/30/2024Wells Fargo & CompanyInitiated CoverageOverweight$18.00
5/14/2024GuggenheimUpgradeNeutral ➝ Buy$13.00
5/10/2024UBS GroupLower TargetBuy ➝ Buy$20.00 ➝ $19.00
5/10/2024Morgan StanleyLower TargetOverweight ➝ Overweight$20.00 ➝ $19.00
5/10/2024Needham & Company LLCReiterated RatingHold
5/10/2024Bank of AmericaLower TargetBuy ➝ Buy$14.00 ➝ $13.00
3/18/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$21.00 ➝ $19.00
2/29/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$22.00
12/19/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$15.00 ➝ $20.00
11/9/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$14.00 ➝ $15.00
10/10/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$15.00 ➝ $14.00
9/29/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$17.00 ➝ $19.00
9/29/2023Bank of AmericaBoost Target$16.00 ➝ $19.00
3/27/2023Bank of AmericaBoost TargetBuy$16.00 ➝ $17.00
3/2/2023UBS GroupBoost TargetBuy$15.00 ➝ $17.00
3/2/2023The Goldman Sachs GroupBoost TargetNeutral$10.00 ➝ $11.00
1/18/2023BTIG ResearchBoost TargetBuy$14.00 ➝ $16.00
11/8/2022Morgan StanleyBoost TargetEqual Weight$14.00 ➝ $15.00
9/9/2022Morgan StanleyInitiated CoverageEqual Weight$14.00
4/13/2022The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral
2/24/2022Leerink PartnersLower TargetOutperform$16.00 ➝ $14.00
1/13/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$12.00 ➝ $16.00
1/13/2022Cantor FitzgeraldLower TargetOverweight$16.00 ➝ $15.00
11/15/2021Stifel NicolausUpgradeHold ➝ Buy$12.00 ➝ $16.00
9/30/2021Leerink PartnersLower TargetMarket Perform$13.00 ➝ $12.00
9/30/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$17.11 ➝ $16.00
7/19/2021BTIG ResearchInitiated CoverageBuy$15.00
7/1/2021Chardan CapitalReiterated RatingNeutral
7/1/2021Berenberg BankInitiated CoverageHold$14.00
6/10/2021Leerink PartnersReiterated RatingHold
5/27/2021Needham & Company LLCInitiated CoverageHold
5/20/2021UBS GroupInitiated CoverageBuy$16.00
4/19/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight
4/13/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight$17.00 ➝ $17.00
3/22/2021Leerink PartnersLower TargetMarket Perform$15.00 ➝ $13.00
3/8/2021Stifel NicolausInitiated CoverageHold$13.00
3/3/2021Robert W. BairdReiterated RatingBuy
3/1/2021Stifel NicolausInitiated CoverageHold$13.00 ➝ $13.00
2/12/2021CitigroupLower Target$27.00 ➝ $16.00
2/12/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$30.00 ➝ $15.00
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00
2/12/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$30.00 ➝ $17.00
12/28/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00 ➝ $30.00
(Data available from 12/18/2020 forward)

News Sentiment Rating

1.44 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 26 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2025
  • 17 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/20/2025
  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2025
  • 16 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2025
  • 31 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2025
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2025
  • 16 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/17/2025
  • 34 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2025

Current Sentiment

  • 34 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $11.00
Low: $10.91
High: $11.14

50 Day Range

MA: $9.31
Low: $8.04
High: $11.00

52 Week Range

Now: $11.00
Low: $5.51
High: $11.14

Volume

6,284,691 shs

Average Volume

5,355,395 shs

Market Capitalization

$3.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Amicus Therapeutics?

The following equities research analysts have issued reports on Amicus Therapeutics in the last twelve months: Cantor Fitzgerald, Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for FOLD.

What is the current price target for Amicus Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Amicus Therapeutics in the last year. Their average twelve-month price target is $17.29, suggesting a possible upside of 57.1%. UBS Group AG has the highest price target set, predicting FOLD will reach $22.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $11.00 for Amicus Therapeutics in the next year.
View the latest price targets for FOLD.

What is the current consensus analyst rating for Amicus Therapeutics?

Amicus Therapeutics currently has 1 sell rating, 1 hold rating, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for FOLD.

What other companies compete with Amicus Therapeutics?

Other companies that are similar to Amicus Therapeutics include Madrigal Pharmaceuticals, Exelixis, BioMarin Pharmaceutical, Repligen and Halozyme Therapeutics. Learn More about companies similar to Amicus Therapeutics.

How do I contact Amicus Therapeutics' investor relations team?

Amicus Therapeutics' physical mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company's listed phone number is (215) 921-7600 and its investor relations email address is [email protected]. The official website for Amicus Therapeutics is www.amicusrx.com. Learn More about contacing Amicus Therapeutics investor relations.